Clinical Trial Update: Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity PEK Fusion Protein Vaccine [Phase 1]

View source ↗

Summary

Phase I open-label study evaluating the safety, tolerability, and immunogenicity of the PEK fusion protein vaccine for cervical intraepithelial neoplasia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Intraepithelial Neoplasia

Drugs mentioned

• PEK Fusion Protein Vaccine (PEK fusion protein vaccine)

Snippet

Sponsor: HealthBanks Biotech Co., Ltd. | Conditions: Cervical Intraepithelial Neoplasia | Phase 1 | Status: UNKNOWN